<DOC>
	<DOCNO>NCT01260220</DOCNO>
	<brief_summary>An isolation-limited segmental antral approach pulmonary vein isolation effective achieve long-term freedom atrial fibrillation standard anatomic , circumferential antral ablation .</brief_summary>
	<brief_title>Randomized Trial Segmental Versus Circumferential Antral Ablation Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description>This randomize control non-inferiority design trial . Follow : Patients stop anti-arrhythmic drug 2 month post procedure . Follow-ups involve clinical assessment , holter and/or loop recorder 3 , 6 , 9 , 12 month interval .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Paroxysmal Atrial Fibrillation ( PAF ) least 6 month least 1 symptomatic episode previous 6 moths Patient must felt candidate Atrial Fibrillation ( AF ) ablation base AF symptomatic refractory intolerant least one class 1 3 antiarrhythmic agent Documentation least one episode AF 12 lead ECG , TTM Holter monitor within 12 month randomization trial Patient must continuous anticoagulation warfarin ( INR 23 ) fractionate subcutaneous heparin &gt; 4 week prior ablation undergone recent ( less 48 hour plan ablation ) transoesphageal echocardiogram exclude leave atrial thrombus . Patient must provide write informed consent participate clinical trial Contraindications oral anticoagulant History previous ablation AF Intracardiac thrombus AF due reversible cause Pregnancy atriotomy scar ( typically , MV TV repair/replacement , ASD surgery , transplant ) ( CABG okay )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>